Literature DB >> 34191085

Acute Pancreatitis as the Initial Presentation of Pancreatic Adenocarcinoma does not Impact Short- and Long-term Outcomes of Curative Intent Surgery: A Study of the French Surgical Association.

Renato Micelli Lupinacci1, Matthieu Faron2, Philippe Bachellier3, Alain Sauvanet4, Alain Beauchet5, Yves-Patrice Le Treut6, Mustapha Adham7, Jean-Yves Mabrut8, Jean-Robert Delpero9, François Paye10.   

Abstract

BACKGROUND: Acute pancreatitis (AP) can be one of the earliest clinical presentation of pancreatic ductal adenocarcinoma (PDAC). Information about the impact of AP on postoperative outcomes as well as its influences on PDAC survival is scarce. This study aimed to determine whether AP as initial clinical presentation of PDAC impact the short- and long-term outcomes of curative intent pancreatic resection. PATIENTS AND METHODS: From 2004 to 2009, 1449 patients with PDAC underwent pancreatic resection in 37 institutions (France, Belgium and Switzerland). We used univariate and multivariate analysis to identify factors associated with severe complications and pancreatic fistula as well as overall and disease-free survivals.
RESULTS: There were 764 males (52,7%), and the median age was 64 years. A total of 781 patients (53.9%) developed at least one complication, among whom 317 (21.8%) were classified as Clavien-Dindo ≥ 3. A total of 114 (8.5%) patients had AP as the initial clinical manifestation of PDAC. This situation was not associated with any increase in the rates of postoperative fistula (21.2% vs 16.4%, P = 0.19), postoperative complications (57% vs 54.2%, P = 0.56), and 30 day mortality (2.6% vs 3.4%, P = 1). In multivariate analysis, AP did not correlate with postoperative complications or pancreatic fistula. The median length of follow-up was 22.4 months. The median overall survival after surgery was 29.9 months in the AP group and 30.5 months in the control group. Overall recurrence rate and local recurrence rate did not differ between groups.
CONCLUSION: AP before PDAC resection did not impact postoperative morbidity and mortality, as well as recurrence rate and survival.

Entities:  

Year:  2021        PMID: 34191085     DOI: 10.1007/s00268-021-06205-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  30 in total

1.  Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox.

Authors:  Stephan Kruger; Karoline Schirle; Michael Haas; Alexander Crispin; Jörg Schirra; Julia Mayerle; Jan G D'Haese; Wolfgang G Kunz; Jens Ricke; Steffen Ormanns; Thomas Kirchner; Sebastian Kobold; Matthias Ilmer; Leonie Gebauer; Christoph B Westphalen; Michael von Bergwelt-Baildon; Jens Werner; Volker Heinemann; Stefan Boeck
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-23       Impact factor: 4.553

2.  Pancreatic Cancer Following Acute Pancreatitis: A Population-based Matched Cohort Study.

Authors:  Omid Sadr-Azodi; Viktor Oskarsson; Andrea Discacciati; Per Videhult; Johan Askling; Anders Ekbom
Journal:  Am J Gastroenterol       Date:  2018-10-12       Impact factor: 10.864

Review 3.  The epidemiology of pancreatitis and pancreatic cancer.

Authors:  Dhiraj Yadav; Albert B Lowenfels
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

Review 4.  Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer.

Authors:  Ilya Gukovsky; Ning Li; Jelena Todoric; Anna Gukovskaya; Michael Karin
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

Review 5.  The pancreas cancer microenvironment.

Authors:  Christine Feig; Aarthi Gopinathan; Albrecht Neesse; Derek S Chan; Natalie Cook; David A Tuveson
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

6.  Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras.

Authors:  Catherine Carrière; Alison L Young; Jason R Gunn; Daniel S Longnecker; Murray Korc
Journal:  Biochem Biophys Res Commun       Date:  2009-03-16       Impact factor: 3.575

7.  Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages.

Authors:  Jun Yu; Amanda L Blackford; Marco Dal Molin; Christopher L Wolfgang; Michael Goggins
Journal:  Gut       Date:  2015-01-30       Impact factor: 23.059

8.  Time to initial cancer treatment in the United States and association with survival over time: An observational study.

Authors:  Alok A Khorana; Katherine Tullio; Paul Elson; Nathan A Pennell; Stephen R Grobmyer; Matthew F Kalady; Daniel Raymond; Jame Abraham; Eric A Klein; R Matthew Walsh; Emily E Monteleone; Wei Wei; Brian Hobbs; Brian J Bolwell
Journal:  PLoS One       Date:  2019-03-01       Impact factor: 3.240

9.  Predictive Role of Tumor Budding in T1 Colorectal Cancer Lymph Node Metastasis.

Authors:  Li-Bin Huang; Ting-Han Yang; Hai-Ning Chen
Journal:  Gastroenterology       Date:  2020-12-30       Impact factor: 22.682

10.  The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data.

Authors:  Axel Bengtsson; Roland Andersson; Daniel Ansari
Journal:  Sci Rep       Date:  2020-10-02       Impact factor: 4.379

View more
  1 in total

Review 1.  The Relationship between Acute and Chronic Pancreatitis with Pancreatic Adenocarcinoma: Review.

Authors:  Tamara Alhobayb; Rahul Peravali; Motaz Ashkar
Journal:  Diseases       Date:  2021-12-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.